Add this result to my export selection NHS England publishes standard operating procedure for administering the Covid-19 vaccine to frontline social care workers (JCVI Priority Cohort 2) (PDF) Source: NHS England (Remove filter) Published by NHS England, 14 January 2021 This SOP outlines the process for facilitating COVID-19 vaccination for frontline social care workers (excluding those working in care homes for older adults), including identification of eligible... Read Summary SPS comment Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants Source: NHS England (Remove filter) Published by NHS England, 20 October 2020 In response to the public health emergency posed by COVID-19, NHS England and NHS Improvement, have set out the interim clinical commissioning position for passive immunisation with palivizumab... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Mercaptamine hydrochloride viscous eyedrops for corneal cystine deposits in people aged older than 2 years Source: NHS England (Remove filter) Published by NHS England, 04 November 2020 Mercaptamine hydrochloride eye drops are not recommended to be available as a treatment option through routine commissioning for corneal cystine deposits due to insufficient evidence, and following... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Defibrotide for severe veno-occlusive disease following stem cell transplant Source: NHS England (Remove filter) Published by NHS England, 04 November 2020 From 1 April 2021, defibrotide is recommended to be available as a treatment option through routine commissioning for severe veno-occlusive disease following stem cell transplant within the criteria... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Sapropterin for phenylketonuria (all ages) Source: NHS England (Remove filter) Published by NHS England, 04 November 2020 Sapropterin is not recommended to be available as a treatment option through routine commissioning for phenylketonuria because though there is sufficient evidence to commission this treatment, ... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection July 2020 Prioritisation Decisions Source: NHS England (Remove filter) Published by NHS England, 04 November 2020 Twice a financial year, NHS England makes decisions on which new specialised treatments should be routinely commissioned. Treatments are grouped into 5 levels of priority; those with highest relative... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages) Source: NHS England (Remove filter) Published by NHS England, 29 October 2020 NHS England has considered the evidence submitted as part of a Preliminary Policy Proposal to establish the Clinical Commissioning Policy Statement and have concluded that there is not enough... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Flash Glucose Monitoring: National arrangements for funding of relevant diabetes patients (updated) Source: NHS England (Remove filter) Published by NHS England, 17 November 2020 This guidance has been updated to include detail on the reimbursement for people with Type 1 diabetes or insulin treated Type 2 diabetes who are living with a learning disability and recorded on... Read Summary Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Rapid policy statement: Ruxolitinib for acute graft versus host disease (PDF) Source: NHS England (Remove filter) Published by NHS England, 04 December 2020 The most common treatment option for corticosteroid-refractory graft versus host disease is extracorporeal photopheresis. Ruxolitinib provides an alternative option which can be taken at home, and... Read Summary SPS comment Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Rapid policy statement: Ruxolitinib for chronic Graft versus Host Disease (PDF) Source: NHS England (Remove filter) Published by NHS England, 11 November 2020 The most common treatment option for corticosteroid-refractory graft versus host disease is extracorporeal photopheresis. Ruxolitinib provides an alternative option which can be taken at home, and... Read Summary SPS comment Type: Policy and Strategy (Add filter) Type: Medicines Current Awareness (Remove filter)